Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Albanese government, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window.
Last mentioned: Aug 1, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Albanese government, the most common co-covered peer. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. At 5, the average consequence score sits below the same-window beat average of 5.7. We currently track 1 Biotech story that mention EnvA, all published on August 1, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 21 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering EnvA. Shared-story counts are live from our verified record — not editorial picks.
Australia's shift to financial biodiversity offsets, with 90% of Queensland obligations paid in cash, accelerates habitat loss that could eliminate undiscovered medicinal compounds, posing a long-term risk to biotech and pharmaceutical companies reliant on natural genetic resources.
Source: australianherald.com · sydneysun.com
EnvA is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
